Complement and Neonatal Fc Receptor Inhibitors in Myasthenia Gravis (MG), Highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials
Dec 13, 2022
1:06:51
Episode Description
Elie Naddaf, MD, interviews James Howard, MD, about the use of complement and the neonatal Fc receptor inhibitors in myasthenia gravis (MG), highlighting CHAMPION MG (ravulizumab) and ADAPT (efgartigimod) trials.
Proudly Supported by
Patrons of Health Podcast Library
Supporting Shows
